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SHORT REPORT
Updated estimate of the duration of the 
meningo-encephalitic stage in gambiense 
human African trypanosomiasis
Francesco Checchi1, Sebastian Funk2*, Daniel Chandramohan1, Daniel T Haydon3 and François Chappuis4,5
Abstract 
Background:  The duration of the stages of HAT is an important factor in epidemiological studies and intervention 
planning. Previously, we published estimates of the duration of the haemo-lymphatic stage 1 and meningo-enceph-
alitic stage 2 of the gambiense form of human African trypanosomiasis (HAT), in the absence of treatment. Here 
we revise the estimate of stage 2 duration, computed based on data from Uganda and South Sudan, by adjusting 
observed infection prevalence for incomplete case detection coverage and diagnostic inaccuracy.
Findings: The revised best estimate for the mean duration of stage 2 is 252 days (95% CI 171–399), about half of our 
initial best estimate, giving a total mean duration of untreated gambiense HAT infection of approximately 2 years and 
2 months. 
Conclusions: Our new estimate provides improved information on the transmission dynamics of this neglected 
tropical disease in Uganda and South Sudan. We stress that there remains considerable variability around the esti-
mated mean values, and that one must be cautious in applying these results to other foci.
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Findings
Human African trypanosomiasis (HAT, sleeping sick-
ness) is a neglected tropical disease that progresses from 
the haemo-lymphatic (early) stage 1 to the ultimately 
fatal, meningo-encephalitic (late) stage 2  [1]. In a previ-
ous paper [2], we reported on the duration of both stages 
of infection with the Trypanosoma brucei gambiense 
form of HAT, which we estimated at 526  (95% CI 357–
833) and 500  (95% CI 345–769) days, respectively. The 
stage 1 duration estimate was based on survival analysis 
of untreated stage 1 serological suspects from Uganda 
and South Sudan foci where Médecins Sans Frontières 
implemented control programmes: We concluded that 
the rate r1 of progression to stage 2 was constant, leading 
to an exponential distribution of stage 1 duration. We 
then derived the stage 2 duration indirectly based on 
the stage 1 to stage 2 ratio as per the following equality, 
resultant from the assumption of endemic equilibrium:
where r2 is the rate of removal from stage 2  (or mortal-
ity rate as death appears to be the only possible outcome 
of untreated stage 2 [3]), also assumed to be constant. In 
order to quantify the S1 to S2 ratio in typical prevalence 
conditions, in our original study we then averaged find-
ings from cross-sectional, active case detection (mass 
screening) sessions performed in villages in Uganda and 
Southern Sudan, only retaining the analysis sessions 
during which >70% of the population had presented for 
testing. Here we present a revised estimate of stage 2 
duration, derived by computing the S1 to S2 ratio based 
on a larger number of screening sessions, without any 
r2 = r1
S1
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screening coverage exclusion criteria; and by adjusting 
observed prevalence data for incomplete screening cov-
erage and diagnostic inaccuracy.
Methods
Data on mass screening sessions were available from HAT 
control projects implemented by Médecins Sans Fron-
tières in Adjumani (Uganda, 1991–1996), Arua-Yumbe 
(Uganda, 1995–2002), and Kiri (South Sudan, 2000–
2005), and furnished values of S1 and S2 as well as other 
analysis parameters. In a recent paper  [4], we developed 
a mathematical modelling method to adjust the S1 and 
S2 prevalence observed in these sessions so as to account 
for (1) incomplete screening coverage, by estimating the 
relative probability of attending screening sessions among 
cases compared to non-cases; and (2) incomplete sen-
sitivity, specificity and staging accuracy of diagnostic 
algorithms, which can result in a combination of false neg-
atives, false positives and stage-misclassified cases among 
persons screened; the diagnostic algorithms used [4] and 
derived accuracy parameters [5] are described elsewhere. 
Note that “screening coverage” here refers to the propor-
tion of the population presenting for testing, and is there-
fore unrelated to how well the screening tests perform.
For this revised analysis, we included screening ses-
sions that yielded at least one case of HAT and were the 
first to be conducted in the respective villages, i.e., in 
epidemiological systems as yet unmodified by control 
(thereby excluding screening sessions done when there 
was also passive surveillance ongoing), where therefore 
the S1–S2 ratio tends to reflect natural progression of the 
disease (ignoring natural mortality, which will occur at 
a much smaller rate than r2). We took the best estimates 
of true S1 and S2 prevalence estimated in [4] for each of 
these screening sessions and summed them across each 
of the above MSF projects, so as to calculate a mean S1
–S2 ratio specific to each HAT focus. We then used this 
ratio and the estimate of r1 from the original study into 
the above equation.
This analysis of secondary programmatic data was 
approved by the Ethics Committee of the London School 
of Hygiene & Tropical Medicine.
Results
Overall, 174 active screening sessions were eligible for 
analysis (Table  1). The ratio of stage 1 and 2 prevalent 
cases ranged from 1.7 (Kiri) to 2.5 (Arua-Yumbe), for 
a mean of 2.09. Using the above equation and our pre-
viously published estimate of r1 (0.0019 per day, 95% 
confidence interval 0.0012–0.0028), the revised stage 2 
progression (death) rate r2 was 0.0040 per day  (95% CI 
0.0025–0.0058). Accordingly, the mean duration of stage 
2 was 1/0.0040 or 252 days (95% CI 171–399), and the 
mean total duration of stage 1 and 2 combined was 778 
days (95% CI 528–1232), or approximately two years and 
two months. Similarly, the median stage 2 duration was 
175 days (95% CI 119–277), giving a total median gam-
biense HAT duration of 539 days (95% CI 367–855), or 
1 year and 6 months.
Discussion
The revised best estimate is about half of that presented 
in our initial publication (albeit with overlapping confi-
dence intervals). While the original estimate was derived 
using only a sub-set of screening sessions, with a cut-off 
for proportion of the population screened, and was based 
on an incomplete adjustment for diagnostic inaccuracy 
of the testing algorithms, the revised estimate includes 
many more sessions and accounts for diagnostic inaccu-
racy. Differences between the two may well be explained 
by including a larger dataset and by avoiding potential 
bias introduced by the cut-off.
However, the revised estimate is otherwise subject to 
the same potential sources of bias discussed at length in 
the original publication [2], which include: (1) bias in the 
estimate of r1, due to high loss to follow-up and possible 
systematic differences between the serologically suspect 
patients included in the analysis of stage 1 duration and 
Table 1 Details of  eligible active screening sessions and  best estimates of  stage 1 and  2 prevalence in  the three areas 
investigated, as well as in all three areas combined (equivalent to treating the three screened populations as one large 
population)
IQR inter-quartile range.
Adjumani, Uganda Arua-Yumbe Uganda Kiri, South Sudan Combined
Number of eligible screening sessions 78 64 32 174
Total population targeted for screening 76,864 163,523 11,231 251,618
Village population: median (IQR) 831 (630–1,074) 2,274 (1,824–2,844) 217 (103–297) 1,041 (571–2035)
Estimated prevalent cases in stage 1 (S1) 731 298 101 1130
Estimated prevalent cases in stage 2 (S2) 363 117 61 541
S1–S2 ratio 2.01 2.55 1.66 2.09
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more typical HAT cases; and (2) bias in the estimate of 
the S1+ to S2 ratio, which relies on assumptions of sta-
ble incidence and homogeneity across different HAT 
foci. We stress that there remains considerable variability 
around the estimated mean values, and that one must be 
cautious in applying the results to other foci.
Further analyses are needed, particularly in light of 
documented differences in the clinical profile and dura-
tion of illness of both gambiense and rhodesiense HAT 
across Sub-Saharan Africa [3, 6, 7]. By applying the model 
to other foci might, it might be possible to obtain more 
general conclusions about the progression of the disease 
and underlying heterogeneities.
Abbreviations
HAT: human African trypanosomiasis; IQR: inter-quartile range; MSF: Médecins 
Sans Frontières; S1: point prevalence of HAT cases in stage 1 of the disease; S2: 
point prevalence of HAT cases in stage 2 of the disease; r1: rate of progression 
from stage 1 to stage 2; r2: rate of removal from stage 2 (through death or 
spontaneous cure)..
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